PolyPid Ltd. (PYPD)
Nasdaq · Healthcare · Biotechnology
$5.20+0.19%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $106M
- 52-week range
- $3.06 – $5.73
- 52-week change
- +55.86%
- EPS (trailing)
- −$1.44
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$34.2M
- Diluted EPS
- $2.09
- Free cash flow
- −$28.1M
From the company’s annual report on SEC EDGAR.
About PolyPid Ltd.
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Headquarters: Petah Tikva, Israel · 69 employees · polypid.com